Russell Investments Group Ltd. lowered its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN – Free Report) by 38.0% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 690,534 shares of the company’s stock after selling 422,360 shares during the period. Russell Investments Group Ltd.’s holdings in Elanco Animal Health were worth $15,463,000 at the end of the most recent reporting period.
A number of other large investors have also added to or reduced their stakes in ELAN. Eurizon Capital SGR S.p.A. increased its holdings in Elanco Animal Health by 139.8% during the 3rd quarter. Eurizon Capital SGR S.p.A. now owns 92,821 shares of the company’s stock valued at $2,080,000 after purchasing an additional 54,111 shares during the period. Maryland State Retirement & Pension System lifted its stake in Elanco Animal Health by 17.1% in the third quarter. Maryland State Retirement & Pension System now owns 30,363 shares of the company’s stock worth $680,000 after acquiring an additional 4,442 shares during the period. Ritholtz Wealth Management boosted its holdings in Elanco Animal Health by 5.0% in the third quarter. Ritholtz Wealth Management now owns 9,335 shares of the company’s stock valued at $209,000 after acquiring an additional 446 shares in the last quarter. New York Life Investment Management LLC boosted its holdings in Elanco Animal Health by 17.7% in the third quarter. New York Life Investment Management LLC now owns 72,257 shares of the company’s stock valued at $1,618,000 after acquiring an additional 10,853 shares in the last quarter. Finally, AlphaCore Capital LLC increased its position in Elanco Animal Health by 16.5% during the 3rd quarter. AlphaCore Capital LLC now owns 21,139 shares of the company’s stock valued at $473,000 after purchasing an additional 2,989 shares during the period. Institutional investors own 97.48% of the company’s stock.
Elanco Animal Health Price Performance
Shares of ELAN opened at $26.32 on Friday. The company has a market capitalization of $13.15 billion, a P/E ratio of -87.72, a price-to-earnings-growth ratio of 2.26 and a beta of 1.73. The firm has a 50 day moving average of $23.59 and a 200 day moving average of $23.92. Elanco Animal Health Incorporated has a twelve month low of $19.40 and a twelve month high of $27.98. The company has a quick ratio of 1.07, a current ratio of 2.09 and a debt-to-equity ratio of 0.55.
Elanco Animal Health (NYSE:ELAN – Get Free Report) last posted its quarterly earnings results on Friday, November 6th. The company reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.20 by $0.07. Elanco Animal Health had a positive return on equity of 8.80% and a negative net margin of 2.86%. The firm had revenue of $1.26 billion during the quarter, compared to analysts’ expectations of $1.21 billion. During the same quarter in the previous year, the business earned $0.19 earnings per share. The company’s revenue was up 11.3% on a year-over-year basis. Elanco Animal Health has set its Q4 2026 guidance at 0.160-0.190 EPS and its FY 2026 guidance at 1.170-1.200 EPS. As a group, equities research analysts anticipate that Elanco Animal Health Incorporated will post 1.18 earnings per share for the current fiscal year.
Elanco Animal Health announced that its Board of Directors has initiated a stock repurchase plan on Thursday, November 19th that allows the company to repurchase $600 million in shares. This buyback authorization allows the company to repurchase up to 4.5% of its shares through open market purchases. Stock buyback plans are often an indication that the company’s leadership believes its shares are undervalued.
Analyst Ratings Changes
Several brokerages have commented on ELAN. Jefferies Financial Group lowered shares of Elanco Animal Health from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $31.00 to $24.00 in a report on Tuesday, October 20th. Barclays increased their price target on shares of Elanco Animal Health from $30.00 to $32.00 and gave the stock an “overweight” rating in a research note on Thursday. UBS Group lifted their price objective on Elanco Animal Health from $31.00 to $33.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Morgan Stanley decreased their target price on Elanco Animal Health from $26.00 to $25.00 and set an “equal weight” rating for the company in a research report on Thursday, October 29th. Finally, Weiss Ratings upgraded Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, September 4th. Nine equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $30.36.
View Our Latest Stock Report on ELAN
Insider Activity
In related news, insider Timothy Bettington sold 4,350 shares of Elanco Animal Health stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $23.00, for a total value of $100,050.00. Following the completion of the sale, the insider owned 138,911 shares of the company’s stock, valued at $3,194,953. The trade was a 3.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.14% of the stock is currently owned by company insiders.
Elanco Animal Health Profile
Elanco Animal Health is a global animal health company that develops, manufactures and markets products for companion animals and livestock. Its offerings include medicines, vaccines and other products intended to prevent and treat disease and support animal health. For pets, Elanco provides treatments for conditions including parasitic infections, pain and chronic diseases. Its livestock products support the health of animals such as cattle, poultry, swine and fish, serving producers and veterinarians.
Featured Articles
- Five stocks we like better than Elanco Animal Health
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN – Free Report).
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.
